News | August 06, 2024
OneSource and BRL ink technology licensing agreement to deliver high-concentration biologics subcutaneously
Revolutionary technology will further boost OneSource’s scientific services offerings
Revolutionary technology will further boost OneSource’s scientific services offerings
Approval is based on data from two Phase III studies in branch and central retinal vein occlusion (RVO) showing early and sustained vision improvements non-inferior to aflibercept
Indoco Remedies is addressing the observations comprehensively and will respond to the USFDA within the stipulated timeframe
EBITDA grew by 31% YoY with EBITDA margin of 11%, a YoY improvement of over 170bps vs. Q1FY24
Zydus receives final approval from USFDA for its NDA Zituvimeta, extended-release tablets
Susvimo is a unique therapeutic approach that provides continuous delivery of medicine to the eye through a refillable implant
The company is planning to expand its plant capacity in in Vapi
Alembic Pharmaceuticals receives 11 USFDA product approval during Q1 FY2025
The expiry date of almost all strips is rubber stamped vanish in a matter of 3 to 4 months, making the remaining tablets waste for subsequent use before expire date
Laurus Labs receives EIR from USFDA for API facilities
Subscribe To Our Newsletter & Stay Updated
